Clinical Trials Logo

Recurrent IDH clinical trials

View clinical trials related to Recurrent IDH.

Filter by:
  • None
  • Page 1

NCT ID: NCT03561870 Completed - Recurrent IDH Clinical Trials

Olaparib in Recurrent IDH-mutant Glioma

OLAGLI
Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

Recent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase (PARP) inhibitors, including olaparib (Lynparza; AstraZeneca). The aim of this open-label phase 2 study is to evaluate the efficacy of olaparib in in recurrent IDH-mutant high grade gliomas based on 6 months progression-free survival.